Overview

Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The trial will investigate the treatment of growth failure in children with Noonan syndrome. Abnormalities in the growth hormone (GH) - insulin-like growth factor-I (IGF-I) axis resulting in low IGF-I levels have been suggested as a possible cause of short stature seen in Noonan syndrome children. Administration of our investigational product is intended to bypass the abnormalities in the GH-IGF axis, and hopefully improve body growth.

Phase:

Phase 2

Details

Lead Sponsor:

Insmed Incorporated

Treatments:

Insulin
Insulin, Globin Zinc
Mecasermin
Mitogens